Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ442MR)

This product GTTS-WQ442MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ442MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ13217MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ14866MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ3952MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ6071MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13235MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11423MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ6601MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW